1. Eisenhauer EA,
Therasse P,
Bogaerts J,
et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version1.1).
Eur J Cancer.
2009;45(2):228-47.
2. Li X,
Abramson RG,
Arlinghaus LR,
et al.
Multiparametric Magnetic Resonance Imaging for Predicting Pathological Response After the First Cycle of Neoadjuvant Chemotherapy in Breast Cancer.
Invest Radiol.
2014 Oct 30; doi: 10.1097/RLI.0000000000000100.
3. Wenkel E,
Uder M,
Janka R.
Diffusionsgewichtete Brustbildgebung.
Der Radiologe.
2014;54(3):224-32.
4. Iwasa H,
Kubota K,
Hamada N,
et al.
Early prediction of response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and gray-scale ultrasonography.
Oncol Rep.
2014;31(4):1555-60.
5. Breast Cancer.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
Version 3.2014.
http://www.nccn.org
6. Nadrljanski M,
Milosevic Z,
Plesinac-Karapandzic V,
et al.
MRI in the evaluation of breast cancer patient response to neoadjuvant chemotherapy: predictive factors for breast conservative surgery.
Diagn Interv Radiol.
2013; 19(6):463-70.
7. Kuerer HM,
Newman LA,
Buzdar AU,
et al.
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
Cancer J Sci Am 1998; 4:230-236.
8. De Bazelaire C,
Pluvinage A,
Chapelier M,
et al.
Diffusion en IRM mammaire.
J Radiol.
2010;91:394-407.
9. BiostaTGV,
Institut Pierre Louis UMR S 1136,
INSERM,
UPMC,
Réseau Sentinelles.
http://marne.u707.jussieu.fr/biostatgv